Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 32s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Recent Developments in Vaccine Development for Viral Diseases: Zika, Ebola, and COVID-19

Parisa Bang[1]

Email ID : bangparisa@gmail.com

Cite this paper as: Parisa Bang, (2025) Recent Developments in Vaccine Development for Viral Diseases: Zika, Ebola, and COVID-19. *Journal of Neonatal Surgery*, 14 (32s), 6958-6967.

ABSTRACT

Viral diseases pose significant threats to global health, often requiring rapid development of vaccines to mitigate outbreaks. The recent advancements in vaccine technologies, such as mRNA platforms, vector-based vaccines, and protein subunit vaccines, have revolutionized approaches to combating diseases like Zika, Ebola, and COVID-19. This paper reviews the scientific progress, challenges, and future directions in vaccine development for these diseases, emphasizing their unique epidemiological contexts and technological innovations.

1. INTRODUCTION

Viral diseases have consistently posed a severe threat to global health, with outbreaks such as Zika, Ebola, and COVID-19 highlighting the pressing need for effective vaccine solutions. Each of these diseases presents unique challenges: Zika's link to congenital abnormalities, Ebola's high mortality rates, and COVID-19's rapid global spread have emphasized the limitations of traditional vaccine development. However, the convergence of biotechnology, computational science, and global cooperation has transformed the landscape, enabling faster, more precise, and scalable vaccine development strategies.

Historically, vaccine creation has been a lengthy process, often spanning decades. The urgency of modern pandemics, however, has catalyzed innovation, reducing timelines from years to months. Emerging platforms like mRNA technology, viral vectors, and protein subunit vaccines have not only enhanced the speed of development but also improved vaccine safety, efficacy, and adaptability. Collaborative efforts among academia, pharmaceutical companies, and governments have further streamlined regulatory pathways and accelerated production.

The recent advancements in vaccine technology underscore a paradigm shift, with these innovations offering hope for addressing future viral threats. This paper provides a comprehensive review of vaccine development for Zika, Ebola, and COVID-19, focusing on the technological breakthroughs, the unique epidemiological challenges of each virus, and the broader implications for global health security.

2. ZIKA VIRUS VACCINE DEVELOPMENT

Zika virus, transmitted primarily through Aedes mosquitoes, became a major public health concern during the 2015–2016 outbreak. The association of Zika infection with microcephaly and other neurological complications in newborns necessitated urgent vaccine development..

Technological Advances: DNA-based vaccines like GLS-5700 and mRNA platforms have shown promise in preclinical and early human trials. Inactivated and live-attenuated vaccines are also under investigation.

Challenges: The transient nature of Zika outbreaks complicates large-scale efficacy trials. Cross-reactivity with other flaviviruses (e.g., dengue) also presents immunological challenges.

Current Status: Several candidates have reached Phase I/II clinical trials, though none are yet widely available or approved.

3. EBOLA VIRUS VACCINE DEVELOPMENT

Ebola virus, known for causing severe hemorrhagic fever with high fatality rates, has prompted intense vaccine development efforts, especially following the 2014–2016 West African outbreak.

The Ebola virus

The Ebola virus is a rare but severe illness in humans and other primates. It is a fatal viral hemorrhagic illness that occurs due to an infection belonging to the filoviridae family. It is known to spread easily due to the large and growing populations in areas

History and name

It was first identified in 1976, in two simultaneous outbreaks, one in Nzara (a town in South Sudan) and the other in Yambuku (the Democratic Republic of Congo). Dr. Peter Piot who was allegedly working on the yellow fever case first identified ebola in the Democratic Republic of Congo, where all other outbreaks in 2017 and 2018 are said to occur. The name "Ebola" was termed as the disease was recognised near the Ebola river in Congo.

The symptoms and recovery

The incubation period is between 2 and 21 days. However, estimates based on models predict that around 5% may take longer than 21 days to develop. Symptoms typically start anywhere between two days and three weeks after infection. Symptoms usually begin with a sudden influenza-like stage indicating fever, sore throat, muscle pain and headaches. These are usually followed by vomiting, diarrhoea(increases the risks of dehydration), abdominal pain, and sometimes hiccups. Furthermore, shortness of breath and chest pain may occur, along with swelling, headaches and confusion. In 50% of cases skin develops a maculopapular rash, in five to seven days after the symptoms begin.

In some cases internal and external bleeding may occur. This usually happens after the first symptoms. Bleeding from mucous membranes or from sites of needle punctures is the most common. This may cause vomiting of blood, coughing up of blood, or blood in stool. Bleeding into the whites of the eyes may also occur.

Recovery may begin between seven and 14 days after first symptoms. Death, if it occurs, follows typically six to sixteen days from first symptoms and is often due to shock from fluid loss. The after effects include, continued tiredness, continued weakness, anorexia, and difficulty returning

Causes and transmission

EVD in humans are caused in humans by four of six viruses of the genus ebolavirus. The four are Bundibugyo virus, Sudan virus, Taï Forest virus, and Ebola virus(the most severe one). The fifth and sixth ones are, Reston virus and Bombali virus; these are not thought to cause humans but have caused disease in other primates.

It is believed that between people, Ebola disease spreads only by direct contact with the blood or other body fluids of a person who has developed symptoms of the disease. Most people spread the virus through blood, feces and vomit. EBOV is thought to infect humans through contact with mucous membranes or skin breaks. Entry points for the virus include the nose, mouth, eyes, open wounds, cuts and abrasions. After infection, endothelial cells, liver cells, and several types of immune cells such as macrophages, monocytes, and dendritic cells are the main targets of attack.

Although it is not entirely clear how Ebola initially spreads from animals to humans, the spread is believed to involve direct contact with an infected wild animal or fruit bat. Animals may become infected when they eat fruit partially eaten by bats carrying the virus.

Immune system

EBOV proteins blunt the human immune system's response to viral infections by interfering with the cells' ability to produce and respond to interferon proteins. When a cell is infected with EBOV, receptors located in the cell's cytosol or outside of the cytosol recognise infectious molecules associated with the virus. EBOV's V24 protein blocks the production of antiviral proteins by preventing the STAT1 signalling protein in the neighbouring cell from entering the nucleus. The VP35 protein directly inhibits the production of interferon-beta. By inhibiting these immune responses, EBOV may quickly spread throughout the body.

Diagnosis

Possible non-specific laboratory indicators of EVD include a low platelet count; an initially decreased white blood cell count followed by an increased white blood cell count; elevated levels of the liver enzymes alanine aminotransferase and aspartate aminotransferase; and abnormalities in blood clotting often consistent with disseminated intravascular coagulation such as a prolonged prothrombin time, partial thromboplastin time, and bleeding time.

The specific diagnosis of EVD is confirmed by isolating the virus, detecting its RNA or proteins, or detecting antibodies against the virus in a person's blood.Isolating the virus by cell culture, detecting the viral RNA by polymerase chain reaction and detecting proteins by enzyme-linked immunosorbent assay are methods best used in the early stages of the disease and also for detecting the virus in human remains.

Prevention and vaccines

An Ebola vaccine, rVSV-ZEBOV, was approved in the United States in December 2019. In December 2016, a study found the VSV-EBOV vaccine to be 95–100% effective against the Ebola virus, making it the first proven vaccine against the disease.It appears to be fully effective ten days after being given. The most common side effects include pain, swelling and redness at the injection site, headache, fever, muscle pain, tiredness and joint pain.

People who care for those infected with Ebola should wear protective clothing including masks, gloves, gowns and

goggles. These measures are also recommended for those who may handle objects contaminated by an infected person's body fluids.

Quarantine, also known as enforced isolation, is usually effective in decreasing spread. Governments often quarantine areas where the disease is occurring or individuals who may transmit the disease outside of an initial area. In the United States, the law allows quarantine of those infected with ebolaviruses.

Prognosis

Death, if it occurs, follows typically six to sixteen days after symptoms appear and is often due to low blood pressure from fluid loss. Early supportive care to prevent dehydration may reduce the risk of death.

Post-Ebola virus syndrome

If an infected person survives the process is quick and complete. However, they are prone to develop the post-Ebola virus infection after the acute phase of the infection.

Prolonged cases are more complicated and the severe an infection is the more long-term problems like, inflammation of the testicles, joint pains, fatigue, hearing loss, mood and sleep disturbances, muscular pain, abdominal pain, menstrual abnormalities, miscarriages, skin peeling, or hair loss.

Ebola can stay in some body parts like eyes, breasts and testicles after infection. Therefore, sexual transmission after recovery is also suspected, although it may be rare.

Management

Treatment is primarily supportive in nature. Early supportive care with rehydration and symptomatic treatment improves survival. Blood products such as packed red blood cells, platelets, or fresh frozen plasma may also be used. Other regulators of coagulation have also been tried including heparin in an effort to prevent disseminated intravascular coagulation and clotting factors to decrease bleeding.

Intensive care is often used in the developed world. This may include maintaining blood volume and electrolytes (salts) balance as well as treating any bacterial infections that may develop. Dialysis may be needed for kidney failure, and extracorporeal membrane oxygenation may be used for lung dysfunction.

The Zika virus

Zika fever is an illness caused by Zika virus. Around 80% of cases are estimated to be asymptomatic, though the accuracy of this figure is hindered by the wide variance in data quality, and figures from different outbreaks can vary significantly. Zika virus is a member of the virus family Flaviviridae. It is spread by daytime-active *Aedes* mosquitoes, such as *A. aegypti* and *A. albopictus*.

History

Zika was first known to infect humans from the results of a serological survey in Uganda, published in 1952. The first true case of human infection was identified by Simpson in 1964, who was himself infected while isolating the virus from mosquitoes. In April 2007, the first outbreak outside of Africa and Asia occurred on the island of Yap in the Federated States of Micronesia, characterized by rash, conjunctivitis, and arthralgia, which was initially thought to be dengue, chikungunya, or Ross River disease.

Symptoms and complications

Symptomatic cases are usually mild and can resemble dengue fever. Symptoms may include fever, red eyes, joint pain, headache, and a maculopapular rash. Symptoms generally last less than seven days. Infection during pregnancy causes microcephaly and other brain malformations in some babies.

It can cause pregnancy issues such as fetal loss, stillbirth and preterm birth. Furthermore, it has also been linked to a neurological disorder called Guillain-Barré syndrome. Although these symptoms last temporarily and most people fully recover, some people affected may end up with permanent damage.

Its transmission

Zika virus can be transmitted through mosquitoes (most common), sexual contact, pregnancy and blood transfusion. Most cases of Zika fever are due to mosquitoes and there are only 2 cases reported because of blood transfusion.

Mosquito

Zika is primarily spread by the female *Aedes aegypti* mosquito, which is active mostly in the daytime. The mosquitoes must feed on blood to lay eggs. The true extent of the vectors is still unknown. Zika has been detected in many more species of Aedes, along with Anopheles coustani, Mansonia uniformis, and Culex perfuscus, although this alone does not incriminate them as vectors.

Research into its ecological niche suggests that Zika may be influenced to a greater degree by changes in precipitation and temperature than dengue, making it more likely to be confined to tropical areas. However, rising global temperatures would allow for the disease vector to expand its range further north, allowing Zika to follow.

Sexual

Zika can be transmitted from men and women to their sexual partners; most known cases involve transmission from symptomatic men to women. The virus replicates in the human testis, where it infects several cell types including testicular macrophages, peritubular cells and germ cells, the spermatozoa precursors. Semen parameters can be altered in patients for several weeks post-symptoms onset, and spermatozoa can be infectious.

Pregnancy

Zika virus can spread by vertical transmission, during pregnancy or at delivery. An infection during pregnancy has been linked to changes in neuronal development of the unborn child. Severe progressions of infection have been linked to the development of microcephaly in the unborn child, while mild infections potentially can lead to neurocognitive disorders later in life.

Diagnosis and prevention

A diagnosis of Zika virus infection can only be confirmed by laboratory tests of blood or other body fluids, and it must be differentiated from cross-reactive related flaviviruses such as dengue virus, to which the patient may have been exposed or previously vaccinated.

Prevention involves decreasing mosquito bites in areas where the disease occurs, and proper use of condoms. This highlights the importance of sexual health education and safe sex practices in areas like these. Efforts to prevent bites include the use of DEET or picaridin - based insect repellent, covering much of the body with clothing, mosquito nets, and getting rid of standing water where mosquitoes reproduce. There is no vaccine.

Demographics- genetically modified mosquitoes

Human Zika virus infection appears to have changed in character while expanding its geographical range. The change is from an endemic, mosquito-borne infection causing mild illness across equatorial Africa and Asia, to an infection causing, from 2007 onwards, large outbreaks, and from 2013 onwards, outbreaks linked with neurological disorders including Guillain-Barré syndrome and microcephaly across the Pacific region and the Americas. The future transmission of Zika infection is likely to coincide mainly with the distribution of Aedes mosquito vectors, although there may be rare instances of person-to-person transmission

There has been an innovation of genetically modified Ae. aegypti mosquitoes containing an anti-Zika virus transgene. This transgene contains a group of small synthetic RNAs that are used to target the genome of Zika virus. The use of this modification has been found to reduce viral infection, dissemination and also transmission rates of this virus.

Treatment plan and vaccine development

Treatment of Zika includes getting plenty of rest, drinking a lot of fluids to stay hydrated, and over-the-counter medicines such as acetaminophen to relieve fever and pain.

As of April 2019, no vaccines have been approved for clinical use, however a number of vaccines are currently in clinical trials. The challenges in developing a safe and effective vaccine include limiting side effects such as Guillain-Barré syndrome, a potential consequence of Zika virus infection. Additionally, as dengue virus is closely related to Zika virus, the vaccine needs to minimize the possibility of antibody-dependent enhancement of dengue virus infection. Vaccines that are currently in clinical trials include: DNA vaccine, purified inactivated vaccine(ZPIV), live attenuated vaccine, mRNA vaccine and viral-vector based vaccine.

One health and Zika virus

In order to understand and effectively respond to the spread of Zika virus, it is important to consider a One Health approach. This approach includes strategies produced through the collaboration of experts in different disciplines.

Specifically, the integrated surveillance of human, animal, and environmental factors can help mitigate Zika virus. A One Health perspective recognizes that human health is greatly impacted by the health of their environment around them, enforcing a multidisciplinary approach to disease prevention and control.

COVID-19

Coronavirus disease is a contagious disease caused by the coronavirus SARS-CoV-2. It was first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan.

History

The first known case was identified in Wuhan, China, in December 2019. The virus is thought to be of natural animal origin, most likely through spillover infection. Most scientists believe the virus spilled into human populations through natural zoonosis, similar to the SARS-CoV-1 and MERS-CoV outbreaks, and consistent with other pandemics in human history. By December 2019, the spread of infection was almost entirely driven by human-to-human transmission.

During the early stages of the outbreak, the number of cases doubled approximately every seven and a half days. Available evidence suggests that the SARS-CoV-2 virus was originally harboured by bats, and spread to humans multiple times from infected wild animals at the Huanan Seafood Market in Wuhan in December 2019.

Symptoms, signs and complications

Common symptoms include coughing, fever, loss of smell (anosmia) and taste (ageusia), with less common ones including headaches, nasal congestion and runny nose, muscle pain, sore throat, diarrhea, eye irritation, and toes swelling or turning purple, and in moderate to severe cases, breathing difficulties. Three common clusters of symptoms have been identified: a respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; and a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhea.

Complications may include pneumonia, acute respiratory distress syndrome, multi-organ failure, septic shock, and death. Cardiovascular complications may include heart failure, arrhythmias (including atrial fibrillation), heart inflammation, thrombosis, particularly venous thromboembolism, and endothelial cell injury and dysfunction. Neurologic manifestations include seizure, stroke, encephalitis, and Guillain–Barré syndrome.

Causes and transmission

COVID-19 is mainly transmitted when people breathe in air contaminated by droplets/aerosols and small airborne particles containing the virus. Transmission is more likely the closer people are. However, infection can occur over longer distances, particularly indoors. If the droplets are above a certain critical size, they settle faster than they evaporate, and therefore they contaminate surfaces surrounding them.

Infectivity can begin four to five days before the onset of symptoms. Infected people can spread the disease even if they are pre-symptomatic or asymptomatic.

Diagnosis

COVID-19 can provisionally be diagnosed on the basis of symptoms and confirmed using reverse transcription polymerase chain reaction or other nucleic acid testing of infected secretions.

Viral testing

The standard methods of testing for presence of SARS-CoV-2 are nucleic acid tests, which detect the presence of viral RNA fragments. The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used.

Imaging

Chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection but are not recommended for routine screening.

Prevention

Preventive measures to reduce the chances of infection include getting vaccinated, staying at home, wearing a mask in public, avoiding crowded places, keeping distance from others, ventilating indoor spaces, managing potential exposure durations, washing hands with soap and water often and for at least twenty seconds, practising good respiratory hygiene, and avoiding touching the eyes, nose, or mouth with unwashed hands.

The vaccine

The COVID-19 vaccines are widely credited for their role in reducing the spread of COVID-19 and reducing the severity and death caused by COVID-19. Common side effects of COVID-19 vaccines include soreness, redness, rash, inflammation at the injection site, fatigue, headache, myalgia (muscle pain), and arthralgia (joint pain), which resolve without medical treatment within a few days. COVID-19 vaccination is safe for people who are pregnant or are breastfeeding.

Social distancing

Social distancing includes infection control actions intended to slow the spread of the disease by minimising close contact between individuals. Methods include quarantines; travel restrictions; and the closing of schools, workplaces, stadiums, theatres, or shopping centres. Individuals may apply social distancing methods by staying at home, limiting travel, avoiding

crowded areas, using no-contact greetings, and physically distancing themselves from others.

Self-isolation

Self-isolation at home has been recommended for those diagnosed with COVID-19 and those who suspect they have been infected. Many governments have mandated or recommended self-quarantine for entire populations. The strongest self-quarantine instructions have been issued to those in high-risk groups.

The treatment

The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, and a growing list of approved medications. Most cases of COVID-19 are mild. In these, supportive care includes medication such as paracetamol or NSAIDs to relieve symptoms (fever, body aches, cough), proper intake of fluids, rest, and nasal breathing. Some people may experience persistent symptoms or disability after recovery from the infection, known as long COVID, but there is still limited information on the best management and rehabilitation for this condition.

Prognosis and risk factors

The severity of COVID-19 varies. The disease may take a mild course with few or no symptoms, resembling other common upper respiratory diseases such as the common cold. Mild cases typically recover within two weeks, while those with severe or critical diseases may take three to six weeks to recover. Among those who have died, the time from symptom onset to death has ranged from two to eight weeks. Abnormal sodium levels during hospitalisation with COVID-19 are associated with poor prognosis: high sodium with a greater risk of death, and low sodium with an increased chance of needing ventilator support.

Genetics plays an important role in the ability to fight off Covid. For instance, those that do not produce detectable type I interferons or produce auto-antibodies against these may get much sicker from COVID-19. Genetic screening is able to detect interferon effector genes. Some genetic variants are risk factors in specific populations.

Immunity

The immune response by humans to SARS-CoV-2 virus occurs as a combination of the cell-mediated immunity and antibody production, just as with most other infections. B cells interact with T cells and begin dividing before selection into the plasma cell, partly on the basis of their affinity for antigen.

December 2019, it remains unknown if the immunity is long-lasting in people who recover from the disease. The presence of neutralising antibodies in blood strongly correlates with protection from infection, but the level of neutralising antibody declines with time. Those with asymptomatic or mild disease had undetectable levels of neutralising antibodies two months after infection.

Technological Advances: The rVSV-ZEBOV vaccine (Ervebo) became the first approved Ebola vaccine. It uses a recombinant vesicular stomatitis virus vector expressing the Ebola virus glycoprotein.

Challenges: Ensuring cold chain storage, addressing public mistrust, and scaling production in outbreak zones remain significant hurdles.

Current Status: Ervebo is now approved and used in ring vaccination strategies during outbreaks. Other vector-based candidates are under development.

4. COVID-19 Vaccine Development COVID-19, caused by SARS-CoV-2, triggered an unprecedented global response leading to the fastest vaccine development in history.

Technological Advances: The mRNA vaccines (Pfizer-BioNTech, Moderna) and adenoviral vector vaccines (AstraZeneca, Sputnik V, J&J) have been game changers. Protein subunit vaccines like Novavax add to the diversity.

Challenges: Variants of concern (e.g., Delta, Omicron), vaccine hesitancy, equitable access, and waning immunity are ongoing issues.

Current Status: Billions of doses have been administered globally. Booster campaigns and variant-specific vaccines are being rolled out.

5. Comparative Analysis While each virus necessitated different vaccine strategies, the commonality lies in the rapid deployment of novel technologies and global partnerships.

Disease	Vaccine Platform	Clinical Approval	Key Challenges

Zika	DNA, mRNA	In Trials	Trial scalability, cross-reactivity
Ebola	rVSV vector	Approved (Ervebo)	Cold chain, production
COVID-19	mRNA, Adenoviral vector	Approved	Variants, distribution

6.Challenges in vaccine development

1. Societal and public health challenges

Vaccine hesitancy

The COVID-19 pandemic has brought vaccine hesitancy to the forefront, with misinformation about safety and efficacy impacting vaccination rates. A Kaiser Family Foundation survey conducted in December 2020 found that 39% of respondents were either hesitant or would not get vaccinated against COVID-19, with misinformation about side effects and concerns about the speed of vaccine development being major drivers of hesitancy. Effective communication strategies are crucial to address these concerns and educate the public on vaccine safety.

Access and equity

Patient and parent barriers to immunization include: parents may lack knowledge about childhood vaccinations, have unreasonable fears about vaccine safety, or lack transportation. They may not be aware of the threat of vaccine-preventable illness or that safe and effective vaccines are available against these diseases. A study of a rural clinic showed that supportive staff, convenient office times, and limited wait time for immunizations contributed to fully immunized children.

2. Scientific and biological challenges

Incomplete understanding of immunity

The human immune system is incredibly complex, with multiple tissues and organs, dozens of different signaling pathways , hundreds of different cells , thousands of different effector molecules, and an effectively infinite ability to recognize foreign antigens —all of which must be “choreographed” effectively, kinetically, and in proper sequence. Immunologists have developed a large and comprehensive (but by no means complete) catalog of the individual parts that make up the system ; however, our reductionist understanding of how these parts collaboratively function as a “system” has lagged behind. While we understand what most of the parts do individually, we have more trouble understanding how each component inter-relates and collectively contributes to the development of immunity at the systems-level. In short, we do not comprehensively understand the rules governing the behavior of the system and therefore cannot reliably and consistently predict the outcome of a given infection or vaccination.

Pathogen variability

The host immune response typically recognizes and responds to a small set of

immunodominant epitopes. For humoral responses, these epitopes are typically the linear or conformational areas that are readily accessible to antibodies. Unfortunately, these areas of the pathogen genome are often hot spots for mutation or recombination events, enabling the pathogen to evade immune responses by displaying modified surface proteins that are no longer recognized by existing antibodies, forcing the immune system to start over. Sequence differences between viral, bacterial, and parasite strains are often found at these locations; therefore, a neutralizing antibody specific to an epitope on the HA protein of one influenza strain will not necessarily bind to or neutralize that same site on another influenza strain. An analogous situation exists for bacteria, where a second strain may possess entirely different virulence factors than the first. The new strain may be effectively invisible to the immune response specific for the first strain. In this manner, strain diversity contributes to antigenic differences that determine whether or not immune responses are cross-protective. Understanding the factors controlling immunodominance and how pathogens exploit this is of critical importance

Host variability

Inter-individual variation in vaccine-specific immune response is known to be influenced by host gene polymorphisms. This genetic variability of the human population gave rise to vaccine-immunogenetics research focused on finding important genetic variants associated with variations in immune responses by assessing relationships between variability in immune response to vaccines and genetic factors. Certainly, population-based candidate gene association studies of vaccine-specific immune responses are beginning to reveal and explain how—and to what degree—variations in innate and adaptive immune responses following vaccination are determined by gene polymorphisms.

The effect of one gene/allele depends on the presence of another gene/allele that may control a phenotype.

3. Logistical and manufacturing challenges

Manufacturing complexity

The most notorious hurdles responsible for vaccine development failures or delays during this transition are two-fold: the complexity of development of the manufacturing process, formulation, and analytical assays and the difficulty of clinical assay optimization. A vaccine construct is not a laboratory-synthesized chemical moiety but a modified live virus or bacterium–or a component thereof–that is intended to induce a protective immune response in a healthy individual. Therefore, the manufacturing process for vaccines inherently involves growth and modification of live organisms or their components, or recombinant protein expression in a live cell line. Biological entities are highly variable, yet the process must be optimized to make vaccine consistently with pre-specified characteristics and purity and commercially viable yields. A formulation in which to suspend the modified organism or protein is needed that is appropriate for parenteral or oral administration and that

stabilizes the entity to support adequate shelf life. Finally, analytical assays to characterize the vaccine and measure the “potency” or dose level that reflects the quantity of the relevant immunologically active component(s) must be developed and validated.

Scale-up and production capacity

The vaccine development process depends on the drug's efficacy, tolerability and safety evaluated in clinical studies which influence the FDA vaccine approval process timeline. Single-use technologies prove to be particularly suitable when it comes to dealing with highly sensitive and expensive materials that need to be handled not only with care but also in sterile conditions. Additionally, single-use technologies provide the flexibility and agility needed in an industry that relies on the possibility to scale up on demand.

7. Future Directions

Universal Vaccine Platforms: Development of flexible, modular vaccine platforms adaptable to multiple viruses.

Pan-Viral Vaccines: Research into vaccines offering broad protection against viral families (e.g., flaviviruses, coronaviruses).

Global Equity: Addressing manufacturing, affordability, and distribution challenges in low-income countries.

Regulatory Innovations: Fast-tracking approvals without compromising safety, using real-world data.

8. Conclusion

The recent progress in vaccine development for Zika, Ebola, and COVID-19 has been transformative, driven by technological innovation and global collaboration. These advancements not only addressed immediate public health crises but also established blueprints for rapid and effective responses to future outbreaks. Continued investment in research, infrastructure, and equitable access is crucial to ensure global preparedness and health security.

REFERENCES

[1] Feldmann, H., & Geisbert, T. W. (2011). Ebola haemorrhagic fever. The Lancet, 377(9768), 849–862. https://doi.org/10.1016/S0140-6736(10)60667-8

[2] Kuhn, J. H., et al. (2019). Filoviruses: A compendium of 40 years of epidemiological, clinical, and laboratory studies. Archives of Virology Supplement, 20, 13–360. https://doi.org/10.1007/978-3-7091-1366-3_2

[3] WHO. (2021). Ebola virus disease. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease

[4] Henao-Restrepo, A. M., et al. (2017). Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). The Lancet, 389(10068), 505–518. https://doi.org/10.1016/S0140-6736(16)32621-6

[5] Piot, P., et al. (2014). Ebola in West Africa: From disease outbreak to humanitarian crisis. The Lancet Infectious Diseases, 14(11), 1034–1035. https://doi.org/10.1016/S1473-3099(14)70939-8

[6] Petersen, L. R., Jamieson, D. J., Powers, A. M., & Honein, M. A. (2016). Zika virus. New England Journal of Medicine, 374(16), 1552–1563. https://doi.org/10.1056/NEJMra1602113

[7] Musso, D., & Gubler, D. J. (2016). Zika virus. Clinical Microbiology Reviews, 29(3), 487–524. https://doi.org/10.1128/CMR.00072-15

[8] Fauci, A. S., & Morens, D. M. (2016). Zika virus in the Americas—Yet another arbovirus threat. New England Journal of Medicine, 374(7), 601–604. https://doi.org/10.1056/NEJMp1600297

[9] Faria, N. R., et al. (2016). Zika virus in the Americas: Early epidemiological and genetic findings. Science, 352(6283), 345–349. https://doi.org/10.1126/science.aaf5036

[10] Zhou, P., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798), 270–273. https://doi.org/10.1038/s41586-020-2012-7

[11] Hu, B., Guo, H., Zhou, P., & Shi, Z. L. (2021). Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology, 19(3), 141–154. https://doi.org/10.1038/s41579-020-00459-7

[12] Gandhi, R. T., Lynch, J. B., & Del Rio, C. (2020). Mild or moderate COVID-19. New England Journal of Medicine, 383(18), 1757–1766. https://doi.org/10.1056/NEJMcp2009249

[13] World Health Organization. (2020). Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019

[14] Polack, F. P., et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine, 383(27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577